Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD5335
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AZD5335 is an investigational antibody-drug conjugate (ADC) developed for the treatment of solid tumors, including ovarian cancer and lung adenocarcinoma. It consists of a human monoclonal antibody targeting folate receptor alpha (FRa; FOLR1), which is overexpressed in certain cancers, conjugated to a camptothecin-based topoisomerase 1 inhibitor payload (AZ14170132). The ADC selectively binds to FRa-expressing tumor cells, delivering the cytotoxic payload directly to these cells and thereby inhibiting DNA topoisomerase I activity. This targeted approach aims to maximize antitumor efficacy while minimizing toxicity to normal tissues. The drug is administered intravenously and is currently in Phase I/II clinical trials for solid tumors, with a primary focus on ovarian cancer[1][2][3][4][5][7].
- Other names
- anti-FRa antibody-drug conjugate AZD5335
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on AZD5335.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD5335.